1 / 1
High-Quality Setmelanotide CAS 920014-72-8: China Suppliers and Factory for MC4R Agonist for Genetic Obesity Treatment Quotes, Service
Product Description
Setmelanotide is a first-in-class melanocortin-4 receptor (MC4R) agonist used to treat a rare genetic obesity disorder caused by a specific gene defect. It helps restore energy balance and weight control in patients by activating the MC4R pathway in the hypothalamus (which plays a central role in regulating hunger, energy expenditure, and weight).
Key features:
- Mechanism of action: Selectively activates MC4R, mimicking the effects of the natural hormone α-melanocyte-stimulating hormone (α-MSH), reducing hunger and increasing satiety.
- Administration method: Subcutaneous injection once daily.
Primary target diseases:
- POMC deficiency obesity (including PCSK1 deficiency)
- LEPR deficiency obesity
- BBSome gene-related obesity (such as Bardet-Biedl syndrome)
Therapeutic Areas
Setmelanotide primarily focuses on rare genetic obesity disorders, specifically including:
Monogenic obesity:
- POMC/PCSK1 deficiency: Patients have insufficient activation of the MC4R pathway due to mutations in the POMC or PCSK1 genes, which manifests as early severe obesity, adrenal insufficiency, etc.
- LEPR deficiency: A defect in the leptin receptor leads to the failure of the leptin signaling pathway, causing intense hunger and uncontrolled weight gain.
Syndrome-related obesity:
- Bardet-Biedl syndrome (BBS): is a multi-system ciliary disorder that is often accompanied by severe obesity, retinopathy, polydactyly, etc.
- Alström syndrome (clinical trial phase): a multisystemic disease similar to BBS, accompanied by early obesity and metabolic abnormalities.
Other MC4R pathway-related obesity:
- Further research is underway on other gene variants involving the MC4R pathway (such as SH2B1, NCOA1, etc.).
Outlook & Development
1. Current market and clinical standing
- Approved indications: FDA and EMA approved for use in obese patients aged 6 years and older with POMC/PCSK1/LEPR deficiency or BBS.
- Efficacy data: In pivotal clinical trials, most patients experienced significant weight loss (≥10%) and substantial improvement in hunger scores.
- Commercialization progress: As a rare disease treatment, it is priced high, but accessibility is gradually being expanded through health insurance negotiations.
2. Expansion of the R&D pipeline
- Generalized MC4R pathway obesity: The TEMPO registry study explores the therapeutic effects on patients with other MC4R pathway gene variants, and may expand the scope of indications in the future.
- Exploring combination therapies: When used in combination with metabolic drugs such as GLP-1 receptor agonists, it may be effective for a wider range of obese individuals (such as those with general obesity and impaired MC4R function).
3. Challenges and Opportunities
- The patient population is extremely small: the market size is limited by the indication for rare diseases, and long-term real-world data is needed to verify the efficacy and safety.
- Administration method: Daily injection may affect compliance, and oral formulation development has not yet made a breakthrough.
- Competitive landscape: GLP-1 drugs (such as smegglutide) dominate the field of general obesity, and setmelanotide needs to consolidate its irreplaceable position in precision medicine.
- A paradigm of precision medicine: As the first obesity therapy targeting a specific genetic defect, it provides a paradigm for gene-guided therapy.
- Expanded indications: If efficacy is demonstrated in more MC4R pathway-related obesity cases, the patient population may be expanded.
- Pediatric market: Growing demand for early intervention for rare childhood obesity.
4. Market Prospects
- In the short term: solidify its position as the standard treatment in the field of rare hereditary obesity, with penetration increasing as genetic testing becomes more widespread.
- Long-term: If the market can be successfully expanded to a wider range of MC4R-related obesity subtypes, or if combination therapies can be developed, the market potential could be further increased. Meanwhile, in-depth research into the MC4R pathway may lead to a new generation of oral or long-acting formulations.
Conclusion
In summary, Setmelanotide is a breakthrough therapy in the field of rare genetic obesity, filling a clinical gap by precisely targeting the MC4R pathway. Its future value will depend on the expansion of its indications, the development of combination therapies, and its deeper positioning in precision obesity medicine.
Frequently Asked Questions (FAQ)
Q1
What is Setmelanotide and how does it work?
Setmelanotide is a first-in-class melanocortin-4 receptor (MC4R) agonist. It works by selectively activating the MC4R pathway in the hypothalamus, mimicking the natural hormone α-MSH to reduce hunger and increase satiety.
Q2
How is Setmelanotide administered?
It is administered via a subcutaneous injection once daily.
Q3
What are the primary genetic diseases treated by this medication?
It primarily targets rare genetic obesity disorders including POMC/PCSK1 deficiency, LEPR deficiency, and BBSome gene-related obesity such as Bardet-Biedl syndrome (BBS).
Q4
Is Setmelanotide approved for children?
Yes, it is FDA and EMA approved for use in obese patients aged 6 years and older with specific genetic deficiencies (POMC/PCSK1/LEPR or BBS).
Q5
What are the current challenges for Setmelanotide in the market?
Main challenges include an extremely small patient population due to its rare disease indication, the daily injection requirement which may affect compliance, and strong competition from GLP-1 drugs in the general obesity field.
Q6
What is the future potential for Setmelanotide?
Future prospects include expanding indications to other MC4R pathway-related obesity subtypes, developing combination therapies with drugs like GLP-1 agonists, and researching new oral or long-acting formulations.
